Silicon Valley VC firm DFJ led the investment in Verge, which is applying machine learning to the development of new drugs for Parkinson's and ALS.
Researchers from the French Parkinson's and Movement Disorders Consortium evaluated the diagnostic yield and cost of a 127-gene panel on nearly 400 patients.
The group will combine VIB's sequencing technology with Verge's machine learning platform to study banked tissue samples at UCSD in a drug discovery effort.
The company hopes to develop saliva-based RNA assays for concussion, Parkinson's disease and autism using biomarkers discovered by its two academic partners.
Using large-scale GWAS data, researchers saw shared genetic contributors for ALS and frontotemporal dementia, as well as ALS and progressive supranuclear palsy.
Amarantus has reacquired LymPro Test, MSPrecise, and NuroPro and said that it plans to assign the assets to a new subsidiary.
The group will work with hospitals to recruit patients with a genetic history of Parkinson's to test for mutations in LRRK2 and GBA, as well as offer genetic counseling.
The partnership includes biopharmaceutical, life science, and non-profit organizations, as well as several US government agencies.
Two studies appearing in JAMA Neurology respectively examined how variants linked to Alzheimer's disease and Parkinson's disease contribute to the conditions.
In Science this week: mutations that allow the malaria parasite to evade treatment, and more.
Sometimes genetic tests give inconclusive results and provide little reassurance to patients, the Associated Press reports.
Vox wonders whether gene-editing crops will be viewed similarly as genetically modified organisms of if people will give them a try.
In Science this week: research regulation and reporting requirement reform, and more.
With H3Africa, Charles Rotimi has been working to bolster the representation of African participants and African researchers in genomics, Newsweek reports.